Govinda Weerakkody

Statistics

Publications

Citations

H-Index

Active since

2006

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

Daiichi-Sankyo (Japan)

Govinda Weerakkody is an author at Eli Lilly (United States) specializing in pharmacology, clinical pharmacology, and adenosine diphosphate-induced platelet aggregation.

ORCID

Publications per year

2006–2025

Publications

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Milton Packer, Michael R. Zile, Christopher M. Kramer et al. · New England Journal of Medicine · 2024 · 783 citations

Pharmacy, Cardiology, Pharmacotherapy +17

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

John T. Brandt, Christopher D. Payne, Stephen D. Wiviott et al. · American Heart Journal · 2006 · 570 citations

Medicine, Pharmacokinetics, Pharmacology +17

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

David S. Small, Nagy A. Farid, Christopher D. Payne et al. · The Journal of Clinical Pharmacology · 2008 · 316 citations

Medicine, Pharmacokinetics, Pharmacology +10

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

Joseph A. Jakubowski, Christopher D. Payne, John T. Brandt et al. · Journal of Cardiovascular Pharmacology · 2006 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

Stephen J. Nicholls, Imre Pávó, Deepak L. Bhatt et al. · New England Journal of Medicine · 2025 · 87 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 7